Table of Contents

company-logo

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Navidea Biopharmaceuticals Dividend Announcement

• Navidea Biopharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Navidea Biopharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Navidea Biopharmaceuticals Dividend History

Navidea Biopharmaceuticals Dividend Yield

Navidea Biopharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Navidea Biopharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Navidea Biopharmaceuticals Financial Ratios

P/E ratio0.03
PEG ratio0.00
P/B ratio-0.03
ROE-173.56%
Payout ratio0.00%
Current ratio0.56
Quick ratio0.51
Cash Ratio0.48

Navidea Biopharmaceuticals Dividend FAQ

Does Navidea Biopharmaceuticals stock pay dividends?
Navidea Biopharmaceuticals does not currently pay dividends to its shareholders.
Has Navidea Biopharmaceuticals ever paid a dividend?
No, Navidea Biopharmaceuticals has no a history of paying dividends to its shareholders. Navidea Biopharmaceuticals is not known for its dividend payments.
Why doesn't Navidea Biopharmaceuticals pay dividends?
There are several potential reasons why Navidea Biopharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Navidea Biopharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Navidea Biopharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Navidea Biopharmaceuticals a dividend aristocrat?
Navidea Biopharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Navidea Biopharmaceuticals a dividend king?
Navidea Biopharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Navidea Biopharmaceuticals a dividend stock?
No, Navidea Biopharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Navidea Biopharmaceuticals stocks?
To buy Navidea Biopharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Navidea Biopharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.